Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
M&A / Property

Pharmather applies for provisional PatchPrint patent

By The Northwire Desk — AI Analysis Mar 26, 2026 · 17:34 PHRM · 0.075 Pharmather Holdings Ltd
PHRM · Price

Executive Summary

  • Pharmather Holdings Ltd. has submitted a provisional patent application to the U.S. Patent and Trademark Office for "PatchPrint," an automated tabletop microneedle patch 3-D printer.
  • The company is evolving from a microneedle patch developer into a broader solution provider, using PatchPrint to support its existing PharmaPatch programs (ketamine, psychedelics, GLP-1, therapeutic peptides) and expand into manufacturing systems and strategic commercial partnerships.
  • Pharmather has initiated discussions with a medical-focused 3-D printer manufacturer to establish supply chain, engineering, and go-to-market pathways for PatchPrint systems.

Key Details

  • Patent Filing: Submitted a provisional patent application (No. 64/015,408) titled "Automated Tabletop Microneedle Patch Printer with Integrated Demolding, Packaging and Multi-Product Cargo-Adaptive Processing."
  • Technology Specifications: PatchPrint is an automated, compact, tabletop system that integrates dispensing, vacuum loading, accelerated drying, automated demoulding, and packaging in a single unit.
  • Target Applications: The system is designed for deployment in pharmaceutical companies, hospitals, compounding pharmacies, and remote settings for medical countermeasures and vaccines. It supports programmable production for small-molecule drugs, proteins, dietary supplements, biologics, and peptides.
  • Existing Programs Supported: The technology supports Pharmather's PharmaPatch programs for ketamine, psychedelic compounds, GLP-1, and therapeutic peptides.
  • Commercialization Strategy: The company is focusing on commercialization, including:
    • Discussions with a medical-focused 3-D printer manufacturer for supply chain and manufacturing support.
    • Advancing peptide microneedle patches.
    • Developing branded wound care and dermatology products for wellness and cosmeceutical applications.
    • Pursuing development and commercial contracts with pharmaceutical/biotech companies, compounding pharmacies, consumer brands, and government agencies.
  • Market Opportunities: Identified opportunities across therapeutics, consumer health, diagnostics, medical countermeasures, peptides, wound care, cosmeceuticals, vaccines, metabolic disorders (diabetes/obesity), and wellness products.

Notable Quotes

  • "This patent filing is an exciting step in Pharmather's evolution into a microneedle patch platform company... With PatchPrint, we are expanding beyond our PharmaPatch product development efforts to build a business spanning manufacturing, formulations, proprietary products and strategic partnerships while also supporting and scaling our existing PharmaPatch programs." — Fabio Chianelli, CEO
Read the original news release →

More from Pharmather Holdings Ltd

May 27, 2026 · 08:01

PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines

Other May 13, 2026 · 10:12

PharmaTher Explores Hantavirus Treatment Amidst Stock Plunge and Strategic Pivots

Other May 13, 2026 · 10:08

PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

Other Apr 21, 2026 · 08:01

Strategic Alignment with Federal Psychedelic Mandate

Regulatory Apr 20, 2026 · 08:01

PharmaTher Seeks Regulatory Tailwinds Amidst Price Slump

Production / Operations Apr 16, 2026 · 08:01

PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

Regulatory